Briefs: Granules India

Granules India received approval from Brazilian Health Regulatory Agency ANVISA

LEO Pharma to acquire Timber Pharmaceuticals

The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million

Jiangsu Hengrui Pharmaceuticals gets NMPA approval of oteseconazole Ccapsules

Oteseconazole Capsules were found to be safe and more effective than fluconazole

Collaborative efforts and equitable access to diagnostic prevention needed to end TB: Dr. Mandaviya

Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB

India's Medical Value sector projected to reach $ 13 billion by 2026: Dr Mandaviya

Need to harmonize traditional and modern medicine to combat alarming health problems

Hikal receives Brazilian GMP certification and USFDA EIR for Bangalore and Panoli facilities

Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US

Lupin actively contributes to alleviating the burden of COPD for patients across the nation

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24

USFDA concludes inspection at Solara's Cuddalore facility with Zero 483 inspectional observations

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023